Cancer Research
New data on Davanat presented at conference
Published in Drug Week, October 21st, 2005
Pro-Pharmaceuticals announced that Eliezer Zomer, PhD, executive vice president, product development and manufacturing will present, "Targeting Lectins, a Clinical Trial of Galactomannan Coadministered with 5-Fluorouracil (5-FU), in Patients with Refractory Solid Tumors, Preclinical and Phase l Results," at the International Society of Oncodevelopmental Biology and Medicine (ISOBM) Conference to be held in Rhodes, Greece.
"The new data indicates Davanat exhibits broad spectrum enhancement of antitumor drugs. Data from the recently finished phase I trial that evaluated advanced patients with a median tumor load of more than 100mm indicates the potential benefit of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-10-21)
More Articles from Drug Week
- Breast Cancer
Arimidex gains U.S. FDA approval for breast cancer in postmenopausal women - Community-Acquired Pneumonia
Data released from phase III trial comparing 5-, 7-day Factive treatment of CAP - Depression Therapy
Utility of IEG mapping in drug classification elucidated - Drug Development
Phase II trial of perifosine with radiotherapy initiated in lung cancer patients - Drug Development
Phenserine does not demonstrate benefit over placebo in Alzheimer disease - Leukemia
Data from phase III trial of Genasense confirm extended durability of remission - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
